Icon introduces new drug safety reporting solution

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/spainter_vfx)
(Image: Getty/spainter_vfx)

Related tags Icon Safety Regulation CRO Pharmacovigilance

Icon’s new drug safety reporting platform automates complex processes to ensure compliance in the ‘ever-changing’ regulatory environment, says VP.

Launched at DIA Europe last week, the solution was received positively, said Quintin Van Wyk, VP of pharmacovigilance and safety reporting at Icon.

“Sponsors are especially interested in the capability to integrate with other clinical trial applications for increased efficiency and the opportunity decrease complexity in the process,”​ he told us.

Wyk said the new cloud-based solution features automated and configurable business rules to distribute “expedited and periodic submissions to all stakeholders,”​ including investigator sites, ethics committees, institutional review boards, and competent authorities.

The system verifies and translates pharmacovigilance regulatory requirements for 80 countries into date-stamped reporting rules to track changing requirements. It also is integrated with Icon’s electronic trial master file (eTMF) for automated filing and provides an auditable distribution trail, among other features that aim to reduce time and effort for study personnel, said Wyk.

“Drug safety reporting is complex due to the evolving, ever-changing regulatory environment,”​ he explained. “Running a clinical study across multiple countries requires careful consideration of global and national country legal pharmacovigilance requirements.”

Wyk noted that it is crucial to stay current with the latest developments, adapting reporting to the required format and deadlines. 

“One country or region may have numerous regulations, directives, laws, guidance and these rules may have overlapping or contradictory requirements,” ​he added. “Appropriate interpretation of pharmacovigilance regulations requires in-depth knowledge of both global and local regulations to decipher the reporting rules and avoid over or under reporting that might affect patient safety.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us

Products

View more

Webinars